unfavourable tuberculosis treatment outcome vary between adolescents (10–17 years) and young adults (18–24 years), and the extent to which they are included in treatment support strategies.

Methods A national retrospective cohort study was conducted using Brazilian tuberculosis registry data to investigate the predictors of unfavourable treatment outcome for young people with tuberculosis. Persons between 10–24 years, with newly diagnosed tuberculosis between January 2015 and December 2018, were included. Unfavourable outcomes were defined as loss to follow-up, treatment failure, change in treatment, death. Favourable outcomes were defined as treatment completion or cure. Factors associated with unfavourable treatment outcome were compared between adolescents and young adults, using complete case and missing indicator multiple logistic regression models.

Results 41,870 young people were included, 7,024 (17%) experienced unfavourable treatment outcomes.

5,869 (14%) were lost to follow-up; of which 86% were young adults, 72% male, 73% identifying with black or brown skin colour, 67% had low educational attainment and 9% diagnosed with HIV/AIDS. HIV/AIDS ($OR_{adj}4.52;95\%$ CI:2.85–7.17), drug use ($OR_{adj}3.66;95\%$ CI:2.36–5.70), identifying with black skin colour ($OR_{adj}2.07;95\%$ CI:1.44–2.98) or low educational attainment ($OR_{adj}2.06;95\%$ CI:1.64–2.59) were most strongly associated with unfavourable outcome in adolescents, as compared to young adults. Conversely, deprivation of liberty was only protective for young adults ($OR_{adj}0.56;95\%$ CI:0.48–0.66). Adolescents and young adults with tuberculosis had similarly low uptake of treatment supervision (52% vs. 52%; p=0.92), however adolescents were more likely to receive governmental cash transfers compared to young adults (17% vs. 1000%, p<0.05).

Conclusions HIV/AIDS, drug use, race and educational attainment are the strongest independent predictors of unfavourable outcome for both adolescents and young adults with tuberculosis in Brazil. Greater efforts are needed to engage vulnerable young people with tuberculosis in treatment support strategies, including treatment supervision and governmental cash transfers.

S11

LONG-TERM FOLLOW-UP OF THE PHASE 1 START TRIAL OF ONASEMNOGENE ABEPARVOVEC GENE THERAPY IN SPINAL MUSCULAR ATROPHY TYPE 1

¹JR Mendell, ²R Shell, ¹KJ Lehman, ¹M McColly, ¹LP Lowes, ¹LN Alfano, ¹NF Miller, ¹MA lammarino, ¹K Church, ³I Kausar, ³SP Reyna, ³M Meriggioli, ³A Kleyn, ⁴S Al-Zaidy. ¹Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA; ²Department of Pediatrics, Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH, USA; ³AveXis, Inc., Bannockburn, IL, USA; ⁴Al-Zaidy and Associates, LLC, Columbus, OH, USA

10.1136/thorax-2020-BTSabstracts.17

Introduction and Objective Onasemnogene abeparvovec (formerly AVXS-101) is designed to address the genetic root cause of spinal muscular atrophy type 1 (SMA1). In the phase 1 trial (START; NCT02122952), patients who received a one-time (proposed therapeutic dose) infusion (n=12) demonstrated significantly improved outcomes versus untreated natural history. Here, we evaluate long-term safety in patients previously treated in START and long-term efficacy in patients from both Cohorts. START patients could electively enroll into a LTFU study (NCT03421977).

Methods Primary objective: long-term safety. Patients have annual visits (5 years) followed by annual phone contact (additional 10 years). Assessments include medical history/record review, physical examination, clinical laboratory evaluation, pulmonary assessments, and milestone maintenance.

Results As of 31 Dec 2019, 13 patients (low dose, n=3; therapeutic dose, n=10) were enrolled. The oldest patients were aged 6.2 (low dose) and 5.6 (therapeutic dose) years. All patients who received the therapeutic dose have survived and are free of permanent ventilation (mean [range] age at last data cut: 4.8 [4.3-5.6] years; mean [range] time since dosing: 4.5 [4.1-5.2] years). These patients have either maintained all previously attained milestones or gained new milestones; 2 patients have newly achieved standing with assistance while not receiving concomitant survival motor neuron 2 protein (SMN2) upregulating therapy at any point. Of the 10 enrolled patients who received therapeutic dose, 6 did not require regular, daily respiratory support more than 4 years after dosing. Additionally, 6 have never received concomitant SMN2 upregulating therapy. No new treatment-related adverse events (AEs) were reported. Onasemnogene abeparvovec has been associated with transient, manageable, and subacute AEs. During LTFU, no AEs of special interest have been reported to date, specifically none associated with liver enzyme elevations, haematology values, new malignancies or autoimmune disorders. Serious AEs were reported in 8/13 (61.5%) patients; however, no serious AEs were considered related to treatment or lead to study discontinuation supporting a favorable riskbenefit profile.

Conclusions Onasemnogene abeparvovec shows a favorable risk-benefit profile, and continues to demonstrate efficacy with new milestone developments.

S12

ONASEMNOGENE ABEPARVOVEC GENE THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1: PHASE 3 STUDY (STR1VE-US)

¹JW Day, ²RS Finkel, ³AM Connolly, ⁴BT Darras, ⁵ST Iannaccone, ⁶NL Kuntz, ⁷LDM Peña, ⁸EC Smith, ⁹CA Chiriboga, ¹⁰TO Crawford, ¹¹PB Shieh, ¹²JM Kwon, ¹³CM Zaidman, ¹⁴M Schultz, ¹⁴I Kausar, ¹⁴D Chand, ¹⁴S Tauscher-Wisniewski, ¹⁴H Ouyang, ¹⁴TA Macek, ¹⁵JR Mendell. ¹Department of Neurology, Stanford University Medical Center, Stanford, CA, USA; ²Translational Neuroscience Program, St. Jude's Children's Research Hospital, Memphis, TN, USA; ³Department of Neurology, Nationwide Children's Hospital, Columbus, OH, USA; ⁴Department of Neurology, Boston Children's Hospital, Boston, MA, USA; ⁵Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA; ⁶Division of Neurology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; ⁷Division of Human Genetics, Cincinnati Children's Hospital, Cincinnati, OH, USA; ⁸Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA; ⁹Division of Pediatric Neurology, Columbia University Medical Center, New York, NY, USA; ¹⁰Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA; ¹¹Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA: 12 Department of Neurology. University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 13 Department of Neurology, Division of Pediatric Neurology, Washington University School of Medicine, St. Louis, MO, USA; 14AveXis, Inc., Bannockburn, IL, USA; 15Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA

10.1136/thorax-2020-BTSabstracts.18

Introduction and Objective Onasemnogene abeparvovec (formerly AVXS-101), is designed to address the genetic root cause of spinal muscular atrophy (SMA), survival motor neuron 1 gene (SMN1) deletion/mutation. Here, we evaluate final data from STR1VE-US (NCT03306277), a multicenter, open-

A10 Thorax 2021;**76**(Suppl 1):A1–A256